Hiba Naveed

Nov 9, 2023 | frontiersin.org | Ryan Ty |Hiba Naveed |Shinichiro Uchiyama |Anastasios Apostolos

1. Introduction Early initiation of antithrombotic medications decreases the risk of recurrence of vascular events in patients with coronary artery disease (CAD), transient ischemic attack (TIA), and ischemic stroke (1–5). Numerous clinical trials during the last 50 years have provided evidence that ASA and clopidogrel reduce the risk of stroke and other vascular events when compared to placebo (6–13).